First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

NCT07516639 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects (HS)
SLE (Systemic Lupus)

Interventions

DRUG: ISH0613 for injection
DRUG: Placebo

Sponsor

SUNHO（China）BioPharmaceutical CO., Ltd.